C
Chris J.L.M. Meijer
Researcher at VU University Amsterdam
Publications - 745
Citations - 83366
Chris J.L.M. Meijer is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Cervical cancer & Cervical intraepithelial neoplasia. The author has an hindex of 128, co-authored 733 publications receiving 78705 citations. Previous affiliations of Chris J.L.M. Meijer include VU University Medical Center & Academic Center for Dentistry Amsterdam.
Papers
More filters
Journal ArticleDOI
Human papillomavirus infection and invasive cervical cancer in Paraguay.
Pedro A. Rolón,Jennifer S. Smith,Nubia Muñoz,Stefanie J. Klug,Rolando Herrero,Xavier Bosch,Fernando Llamosas,Chris J.L.M. Meijer,Jan M. M. Walboomers +8 more
TL;DR: Results of a further IARC case‐control study conducted in Asunción, Paraguay, to examine the association between specific HPV types and invasive cervical cancer as well as risk factors other than HPV found strong associations were found.
Journal ArticleDOI
Clinical utility of HPV genotyping.
TL;DR: There is now compelling evidence that testing for oncogenic HPV is more sensitive and has a higher negative predictive value (NPV) for CIN2 or worse (CIN2+) compared to cervical cytology at the cost of a small decrease in specificity and positive predictive value compared to cytology.
Journal ArticleDOI
Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
TL;DR: Results demonstrate that the neoplastic cells in most primary cutaneous CD30-positive (anaplastic) large T-cell lymphomas and lymphomatoid papulosis have a unique CD4+, CD8-, cytotoxic T- cell phenotype.
Journal ArticleDOI
Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNA–Positive Women
Albertus T. Hesselink,Daniëlle A.M. Heideman,Renske D.M. Steenbergen,Veerle M.H. Coupé,Renée M Overmeer,D.C. Rijkaart,Johannes Berkhof,Chris J.L.M. Meijer,Peter J.F. Snijders +8 more
TL;DR: An objective methylation marker panel was developed that was equally discriminatory for CIN3+ as cytology or cytology with HPV16/18 genotyping in hrHPV-positive women, opening the possibility for complete cervical screening by objective, nonmorphological molecular methods.
Journal ArticleDOI
New technologies and procedures for cervical cancer screening.
Jack Cuzick,Christine Bergeron,Magnus von Knebel Doeberitz,Patti E. Gravitt,Jose Jeronimo,Attila T. Lorincz,Chris J.L.M. Meijer,Rengaswamy Sankaranarayanan,Peter J. F. Snijders,Anne Szarewski +9 more
TL;DR: If HPV testing is to reach its full potential, new approaches with better specificity are needed, either as triage tests for HPV positive women or, if the high sensitivity of HPV DNA testing can be maintained, as alternate primary screening modalities.